Welcome to our dedicated page for ASSEMBLY BIOSCIENCES SEC filings (Ticker: ASMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASSEMBLY BIOSCIENCES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASSEMBLY BIOSCIENCES's regulatory disclosures and financial reporting.
ASSEMBLY BIOSCIENCES, INC. principal financial and accounting officer Jeanette M. Bjorkquist reported a small sale of 29 shares of common stock at $23.25 per share. The sale was executed solely to cover tax withholding on vested restricted stock units under a mandatory sell-to-cover rule, and she still holds 14,560 shares directly.
Gaggar Anuj reported acquisition or exercise transactions in this Form 4 filing.
Assembly Biosciences Chief Medical Officer Anuj Gaggar reported an equity compensation grant in the form of 14,000 shares of common stock at a price of $0.00 per share. These shares reflect restricted stock units that became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.
The RSUs vest in four approximately equal installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service. Following this award and prior ESPP purchases, Gaggar now holds 42,688 common shares directly, indicating a routine compensation-related increase in ownership.
White Nicole S reported acquisition or exercise transactions in this Form 4 filing.
Assembly Biosciences reported that Chief Manufacturing Officer Nicole S. White received a grant of 14,000 shares of common stock in the form of restricted stock units as part of her annual equity compensation. The RSUs were approved on March 29, 2026 and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.
The RSUs vest in four approximately equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming she remains in continuous service. Following this grant and an administrative correction that removed 3,332 shares from prior totals, she now directly holds 48,145 shares of common stock.
Assembly Biosciences director John G. McHutchison received a grant of stock options for 8,000 shares of Common Stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders.
ASSEMBLY BIOSCIENCES, INC. director Susan Mahony received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.
The options vest, assuming continuous service, upon the earlier of June 4, 2027 or the date of the company’s 2027 annual meeting of stockholders. Following this grant, Mahony holds 8,000 stock options directly.
Assembly Biosciences director Lisa Johnson-Pratt received a grant of stock options for 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting. Following this grant, she holds 8,000 stock options directly.
ASSEMBLY BIOSCIENCES, INC. director Michael Houghton received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036. They vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Houghton holds 8,000 stock options directly.
ASSEMBLY BIOSCIENCES, INC. director Gina Consylman received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and represent compensation rather than an open-market purchase.
The options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Consylman holds 8,000 stock options directly, with an expiration date in 2036.
Assembly Biosciences, Inc. reported that director Anthony E. Altig received a grant of stock options to acquire 8,000 shares of Common Stock. The options have an exercise price of $24.11 per share and expire on June 4, 2036.
These options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Altig holds stock options for 8,000 underlying shares directly.
Assembly Biosciences, Inc. reported that its Principal Financial Officer and Principal Accounting Officer, Jeanette M. Bjorkquist, acquired 3,500 shares of common stock at no cost through a grant of restricted stock units. These RSUs represent 35% of her annual equity grant and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan that increased the shares authorized under the plan. The RSUs vest in four approximately equal installments on March 29 of each year from 2027 through 2030, assuming she remains in continuous service. Following this grant, Bjorkquist directly holds 14,589 shares of common stock.